KR20130041385A - Ｓ１ｐ 수용체 효능제의 투여 용법 - Google Patents

Ｓ１ｐ 수용체 효능제의 투여 용법 Download PDF

Info

Publication number
KR20130041385A
KR20130041385A KR1020137008529A KR20137008529A KR20130041385A KR 20130041385 A KR20130041385 A KR 20130041385A KR 1020137008529 A KR1020137008529 A KR 1020137008529A KR 20137008529 A KR20137008529 A KR 20137008529A KR 20130041385 A KR20130041385 A KR 20130041385A
Authority
KR
South Korea
Prior art keywords
alkyl
agonist
substituted
dose
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137008529A
Other languages
English (en)
Korean (ko)
Inventor
존 엠. 코바릭
질케 아펠-딩게만제
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130041385(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20130041385A publication Critical patent/KR20130041385A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
KR1020137008529A 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법 Ceased KR20130041385A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29
US60/631,483 2004-11-29
PCT/US2005/043044 WO2006058316A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011969A Division KR20070085465A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147018084A Division KR20140095109A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법

Publications (1)

Publication Number Publication Date
KR20130041385A true KR20130041385A (ko) 2013-04-24

Family

ID=36046868

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020137008529A Ceased KR20130041385A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법
KR20157005416A Ceased KR20150028858A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법
KR1020077011969A Ceased KR20070085465A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법
KR1020147018084A Withdrawn KR20140095109A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR20157005416A Ceased KR20150028858A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법
KR1020077011969A Ceased KR20070085465A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법
KR1020147018084A Withdrawn KR20140095109A (ko) 2004-11-29 2005-11-28 Ｓ１ｐ 수용체 효능제의 투여 용법

Country Status (21)

Country Link
US (3) US20090275553A1 (enExample)
EP (3) EP1819326B1 (enExample)
JP (4) JP2008521827A (enExample)
KR (4) KR20130041385A (enExample)
CN (2) CN102600472A (enExample)
AU (1) AU2005309378B2 (enExample)
BR (1) BRPI0518674A2 (enExample)
CA (1) CA2589265A1 (enExample)
ES (1) ES2495690T3 (enExample)
IL (2) IL183134A0 (enExample)
MA (1) MA29034B1 (enExample)
MX (1) MX2007006373A (enExample)
NO (2) NO20072401L (enExample)
NZ (2) NZ554720A (enExample)
PL (1) PL1819326T3 (enExample)
PT (1) PT1819326E (enExample)
RU (2) RU2478384C2 (enExample)
SG (2) SG158096A1 (enExample)
TN (1) TNSN07209A1 (enExample)
WO (1) WO2006058316A1 (enExample)
ZA (1) ZA200703328B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781595A1 (en) 2004-08-13 2007-05-09 Praecis Pharmaceuticals Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
CN102600472A (zh) * 2004-11-29 2012-07-25 诺瓦提斯公司 S1p受体激动剂的剂量方案
MX2008003170A (es) * 2005-09-09 2008-03-18 Novartis Ag Tratamiento de enfermedades autoinmunes.
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR101526835B1 (ko) * 2007-05-04 2015-06-05 노파르티스 아게 Ｓ1ｐ 수용체 조절제의 용도
AR070842A1 (es) * 2008-03-17 2010-05-05 Actelion Pharmaceuticals Ltd Regimen de dosificacion para un agonista de receptor selectivo de s1p1
TW201000109A (en) * 2008-05-20 2010-01-01 Kyorin Seiyaku Kk Agent for induction/maintenance of remission
SI2307007T1 (sl) 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
EP2326325B1 (en) 2008-08-18 2014-11-12 Novartis AG Azetidine derivative for the treatment of peripheral neuropathies
CA2747558A1 (en) 2008-12-18 2010-07-15 Novartis Ag New salts
KR20110096584A (ko) * 2008-12-18 2011-08-30 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
JP2012512884A (ja) 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
PT4098256T (pt) * 2008-12-22 2025-04-10 Novartis Ag Regime de dosagem para um agonista do recetor de s1p
CN105213372A (zh) * 2008-12-22 2016-01-06 诺华股份有限公司 S1p受体激动剂的给药方案
JP2013505983A (ja) * 2009-09-29 2013-02-21 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターの投与計画
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
EP2566473B1 (en) * 2010-05-06 2016-01-06 Novartis AG Dosage regimen of diaryl sulfide derivatives
UA114283C2 (uk) 2011-01-07 2017-05-25 Новартіс Аг Композиції імуносупресантів
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
HRP20200883T1 (hr) 2012-08-17 2020-09-04 Actelion Pharmaceuticals Ltd. Postupak za pripremanje (2z,5z)-5-(3-kloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međuproizvodi koji se koriste u navedenom postupku
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
UA122064C2 (uk) 2014-12-11 2020-09-10 Актеліон Фармасьютікалз Лтд Схема дозування для селективного агоніста рецептора s1p1
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
SK282225B6 (sk) * 1995-12-28 2001-12-03 Welfide Corporation Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
SI0990440T1 (sl) * 1997-02-27 2009-04-30 Novartis Ag Farmacevtski sestavek, ki obsega 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol, lecitin in saharid
SI1319651T1 (en) 1997-04-04 2005-10-31 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
SK152003A3 (en) 2000-07-13 2004-07-07 Sankyo Co Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
IL157773A0 (en) 2001-03-26 2004-03-28 Novartis Ag 2-amino-propanol derivatives
DE60211139T2 (de) * 2001-04-02 2007-03-01 Astrazeneca Ab Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
EP2359849A1 (en) * 2001-04-02 2011-08-24 Genentech, Inc. Combination therapy
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
RU2003136730A (ru) * 2001-06-08 2005-05-20 Новартис АГ (CH) Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата
CN1329372C (zh) 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
CN102526079B (zh) * 2002-09-24 2014-06-18 诺华股份有限公司 治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
TW200505442A (en) 2003-05-19 2005-02-16 Genomics Inst Of The Novartis Res Foundation Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
CN102600472A (zh) * 2004-11-29 2012-07-25 诺瓦提斯公司 S1p受体激动剂的剂量方案
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Also Published As

Publication number Publication date
MA29034B1 (fr) 2007-11-01
JP2015061883A (ja) 2015-04-02
JP2012107059A (ja) 2012-06-07
NZ590054A (en) 2012-07-27
EP2359821A1 (en) 2011-08-24
KR20150028858A (ko) 2015-03-16
CN101068536A (zh) 2007-11-07
AU2005309378A1 (en) 2006-06-01
RU2478384C2 (ru) 2013-04-10
JP2008521827A (ja) 2008-06-26
IL223502A0 (en) 2013-02-03
SG187468A1 (en) 2013-02-28
ES2495690T3 (es) 2014-09-17
KR20140095109A (ko) 2014-07-31
CN101068536B (zh) 2012-12-05
NO20121305L (no) 2007-06-22
NZ554720A (en) 2011-04-29
MX2007006373A (es) 2007-06-20
NO20072401L (no) 2007-06-22
HK1109057A1 (en) 2008-05-30
BRPI0518674A2 (pt) 2008-12-02
US20150087720A1 (en) 2015-03-26
TNSN07209A1 (en) 2008-11-21
PL1819326T3 (pl) 2014-12-31
KR20070085465A (ko) 2007-08-27
JP2013129664A (ja) 2013-07-04
AU2005309378B2 (en) 2010-02-11
RU2007124327A (ru) 2009-01-10
CN102600472A (zh) 2012-07-25
US20120071446A1 (en) 2012-03-22
WO2006058316A1 (en) 2006-06-01
IL183134A0 (en) 2008-04-13
CA2589265A1 (en) 2006-06-01
PT1819326E (pt) 2014-09-25
EP2384749A1 (en) 2011-11-09
EP1819326A1 (en) 2007-08-22
SG158096A1 (en) 2010-01-29
ZA200703328B (en) 2008-08-27
EP1819326B1 (en) 2014-07-02
US20090275553A1 (en) 2009-11-05
RU2012141951A (ru) 2014-04-10

Similar Documents

Publication Publication Date Title
KR20130041385A (ko) Ｓ１ｐ 수용체 효능제의 투여 용법
KR101473494B1 (ko) 액상 제제
CN1893934B (zh) 1-磷酸-鞘氨醇（s1p）受体激动剂用于制备治疗脑变性性疾病的药物的应用
KR101526835B1 (ko) Ｓ1ｐ 수용체 조절제의 용도
KR20210010956A (ko) 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
HK1161247A (en) Dosage regimen of an s1p receptor agonist
HK1158943A (en) Dosage regimen of an s1p receptor agonist
HK1109057B (en) Dosage regimen of an s1p receptor agonist
HK1123188B (en) Liquid formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130403

Application number text: 1020077011969

Filing date: 20070528

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130503

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130616

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130616

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140530

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140227

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20140701

Appeal identifier: 2014101003316

Request date: 20140530

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140630

Application number text: 1020077011969

Filing date: 20070528

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20140701

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20140701

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2014101003316

Request date: 20140530

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20140701

WITB Written withdrawal of application